February 6, 2024 10:23 AM EST
News Briefing

Im­munome buys desmoid tu­mor as­set; UK looks in­to Ther­mo Fish­er-Olink deal; Kyver­na's up­sized IPO

Jaimy Lee

Deputy Editor

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Plus, news about At­tralus, Sang­amo, Mithra, NeOnc, 4D Mol­e­c­u­lar Ther­a­peu­tics and Im­mix Bio­phar­ma:

Im­munome buys Ay­ala’s desmoid tu­mor as­set: The biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times